Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Curis (NASDAQ:CRIS) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Curis in a report on Tuesday, December 10th.

Curis Stock Performance

Curis stock opened at $2.32 on Friday. The business’s 50-day simple moving average is $3.04 and its 200-day simple moving average is $3.88. Curis has a 52 week low of $2.30 and a 52 week high of $17.49. The firm has a market capitalization of $19.64 million, a PE ratio of -0.30 and a beta of 3.49.

Institutional Trading of Curis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CM Management LLC boosted its holdings in Curis by 83.3% during the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after buying an additional 100,000 shares during the last quarter. Focused Wealth Management Inc raised its position in shares of Curis by 9.5% in the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after acquiring an additional 5,138 shares during the period. Millennium Management LLC boosted its stake in Curis by 92.6% during the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 12,287 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Curis during the fourth quarter valued at approximately $35,000. Finally, Alyeska Investment Group L.P. acquired a new position in Curis during the fourth quarter valued at approximately $607,000. 29.97% of the stock is currently owned by institutional investors and hedge funds.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.